Table 2.

Input parameters.

	Preventable Fraction of Desease
Parameter	Base-Case Value	Min–Max	Source
Vaccine Efficacy data (Reduction rate)
CIN2+	97.1%	83.5–99.9	RCP Gardasil 9®
Cervical cancer	97.4%	85–99.9	RCP Gardasil 9®
NIV2+	100%	55.5–100	RCP Gardasil 9®
Vaginal cancer	97.4%	85–99.9	RCP Gardasil 9®
Vulvar cancer	97.4%	85–99.9	RCP Gardasil 9®
Penis cancer	100%	52–100	RCP Gardasil®
Anus cancer	74.9%	8.8–95.4	RCP Gardasil 9®
Oropharyngeal cancer	77.5%	39.6–93.3	RCP Gardasil 9®
Genital condylomas	99%	96.2–99.9	RCP Gardasil 9®
Recurrent respiratory papillomatosis	90.7%	81–100%	Assumption
Annual outpatient cost
CIN2+	EUR 498	+/−20%	[14]
NIV2+, CIS	EUR 498	+/−20%	[14]
Cervical Cancer	EUR 202	+/−20%	[14]
Vulvar + vaginal cancer	EUR 202	+/−20%	[14]
Penis cancer	EUR 202	+/−20%	[14]
Anus cancer	EUR 279	+/−20%	[14]
Oropharyngeal cancer	EUR 202	+/−20%	[14]
Genital condylomas	EUR 704	+/−20%	[14]
Recurrent respiratory papillomatosis	EUR 202	+/−20%	[14]
Annual indirect cost
CIN2-3	EUR 8333	+/−20%	[16]
NIV2+, CIS	EUR 8333	+/−20%	[16]
Cervical Cancer	EUR 9130	+/−20%	[16]
Vulvar + vaginal cancer	EUR 9122	+/−20%	[16]
Penis cancer	EUR 9131	+/−20%	[16]
Anus cancer	EUR 9128	+/−20%	[16]
Oropharyngeal cancer	EUR 9310	+/−20%	[16]
Genital condylomas	-	-	[16]
Recurrent respiratory papillomatosis	EUR 9310	+/−20%	[16]
HPV9 related disease
CIN2+	82.3%	+/−20%	[17,18]
Cervical Cancer	89.1%	+/−20%	[17,18]
NIV2+	94.4%	+/−20%	[17,18]
Vaginal cancer	67.9%	+/−20%	[17,18]
Vulvar cancer	45.3%	+/−20%	[17,18]
Penis cancer	46.3%	+/−20%	[17,18]
Anus cancer	94.4%	+/−20%	[17,18]
Oropharyngeal cancer	23.4%	+/−20%	[17,18]
Genital condylomas	90%	+/−20%	[17,18]
Recurrent respiratory papillomatosis	100%	+/−20%	[17,18]